Cardiac asthma

DUBLIN--( BUSINESS WIRE )--The "Global Atrial Fibrillation Market Size, Share & Industry Trends Analysis Report by End-user, Type, Technology, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The Global Atrial Fibrillation Market size is expected to reach $2.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period. A-fib may not show any symptoms in many people. However, A-fib may result in palpitations, a quick, hammering pulse, shortness of breath, or weakness. Atrial fibrillation episodes can be intermittent or recurrent. Even though A-fib is often not a life-threatening illness, it is a significant medical issue that has to be treated properly to avoid stroke. Medication, therapy to correct the heart rhythm, and catheter operations to obstruct incorrect cardiac signals are all possible forms of treatment for atrial fibrillation. A person with atrial fibrillation may also experience atrial flutter, a similar heart rhythm issue. Despite being a distinct arrhythmia, atrial flutter can be treated in a manner that is quite similar to that of atrial fibrillation. An abnormal heart rhythm (arrhythmia) known as atrial fibrillation (AF or A-fib) is defined by the fast and erratic beating of the atrial chambers of the heart. Short bouts of aberrant beating are frequently the first to appear, and over time, they often grow longer or never stop. It could also begin as another type of arrhythmia, such as atrial flutter, before changing into AF. Episodes could not show any symptoms. COVID-19 Impact Analysis Production of various atrial fibrillation products was slowed down by the COVID-19 outbreak. In addition, fewer COVID-19 cases are anticipated in the future with the introduction of the COVID-19 vaccine to the market. As a consequence, atrial fibrillation-specific businesses have reopened and are operating at full capacity. To respond to urgent events and develop new working methods, equipment and machinery producers must concentrate on safeguarding their workers, operations, and supply networks in the wake of the decline in COVID-19 infection cases. Market Growth Factors: Increasing prevalence of obesity and cardiac disorders The widespread increase in obesity and cardiac disorders is a major driver of the atrial fibrillation industry. Additionally, cardiac illnesses are one of the leading causes of death worldwide, and their prevalence is increasing quickly as a result of changing lifestyles. Obesity is linked to an elevated likelihood of developing cardiovascular disease (CVD), especially coronary heart disease and heart failure (HF) (CHD). The processes through which obesity raises the risk of CVD include modifications to body composition that may impact hemodynamics and modify the anatomy of the heart. The geriatric population has increased quickly Globally, the number of elderly people is steadily rising. The number of adults 65 and over in the globe was estimated at 703 million in 2019 by the UN organization. In the world's population, those 65 and older now make up 9% of the total, up from 6% in 1990. That number is predicted to increase to 16% by 2050, which would mean that one in every six people on the planet will be 65 or older. Marketing Restraining Factor: Expensive therapy cost of atrial fibrillation This technology is undoubtedly assisting in the market's outgrowth, but one aspect that is restricting expansion is the excessively expensive cost of the treatment procedure. Because it is expensive, it is not always appropriate to utilize it extensively. The first year following an atrial fibrillation diagnosis had the greatest expenses. The main cost component was the cost of admission, with the prices of the primary economy and medications only making up modest portions. Scope of the Study Market Segments Covered in the Report: By End User Hospitals Specialty Clinics Others By Type Surgical Non-Surgical By Technology Radiofrequency Laser Cryotherapy Others By Geography North America US Canada Mexico Rest of North America Europe Germany UK France Russia Spain Italy Rest of Europe Asia Pacific China Japan India South Korea Singapore Malaysia Rest of Asia Pacific LAMEA Brazil Argentina UAE Saudi Arabia South Africa Nigeria Rest of LAMEA Key Market Players List of Companies Profiled in the Report: Johnson & Johnson MicroPort Scientific Corporation Boston Scientific Corporation Abbott Laboratories Medtronic PLC BIOTRONIK SE & Co. KG Koninklijke Philips N.V. Siemens Healthineers AG (Siemens AG) AtriCure, Inc. For more information about this report visit https://www.researchandmarkets.com/r/nh78hs

DUBLIN, Aug. 16, 2022 /PRNewswire/ -- The "Cardiac POC Testing Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Cardiac POC Testing Devices Market to Reach US$1.7 Billion by the Year 2026 Cardiac POC testing devices help in assessing cholesterol and blood glucose levels. Cardiac POC assay test kits deliver accurate results promptly and cost-effectively with standardization for minimizing operational errors. Cardiac POC diagnostic kits are finding increasing application in emerging countries with remote geographical areas, dearth of skilled medical personnel and testing laboratory infrastructure. The increasing adoption of sensitivity and premium-priced POC Troponin tests is contributing to the growth of the global market. The growing move towards value-based and efficient healthcare service delivery against the backdrop of stringent budgets is boosting the prospects for POC Cardiac testing market. Moreover, the majority of medical professionals opt of POC cardiac testing to quickly monitor the condition of patients experiencing chest pain or other heart ailment symptoms in emergency care environments. The global phenomenon of the burgeoning aging populace is driving demand for POC test kits for use in home healthcare and old age homes. Growing patient awareness and the increasing availability of over the counter POC tests is a major factor propelling the POC tests market. At a time when the global healthcare industry is transitioning from disease treatment to disease prevention through increased involvement with patients, POC diagnostic kits are playing an instrumental role in reducing the risk of occurrence and the intensity of prevailing diseases by facilitating prompt diagnosis and earlier clinical intervention. Amid the COVID-19 crisis, the global market for Cardiac POC Testing Devices estimated at US$1.4 Billion in the year 2022, is projected to reach a revised size of US$1.7 Billion by 2026, growing at a CAGR of 5.8% over the analysis period. The U.S. Market is Estimated at $531.3 Million in 2022, While China is Forecast to Reach $192.6 Million by 2026 The Cardiac POC Testing Devices market in the U.S. is estimated at US$531.3 Million in the year 2022. The country currently accounts for a 37.36% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$192.6 Million in the year 2026 trailing a CAGR of 7.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR while Rest of European market (as defined in the study) will reach US$204.7 Million by the end of the analysis period. The United States represents the largest market, driven by high prevalence of cardiovascular diseases, higher levels of physician and patient awareness, favorable government policies, and high usage of cardiac tests. The Asia Pacific region is also growing steadily on account of the increasing awareness about cardiac diagnosis and treatment as well as rising healthcare expenditure. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Rising Incidence, Mounting Economic and Social Burden of Cardiovascular Disease to Drive Market Growth Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017 Leading Causes of Mortality for Low-Income and High-Income Countries Aging Global Population at High Risk of Cardiac Illnesses Present Favorable Outlook for Cardiac POC Testing Devices Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 Technological Advances to Drive the Cardiac POC Diagnostics Market An Overview of Available Quantitative and Qualitative POC Devices for Measuring Multiple Cardiac Markers Increasing Demand for Troponin Tests Drive the Cardiac POC Market Evolution of the Troponin Assay Implementation of Unique & new Troponin-Based Tests Helps in Diagnosing MI Optimizing Novel Troponin Assay Benefits Troponin Applications: A Promising Future Brain Natriuretic Peptide (BNP) Test Registers Significant Growth Myoglobin Test Myoglobin Test Cardiac Biomarker Play Critical Role in Stroke Diagnosis 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Abbott Laboratories ACON Laboratories, Inc. Alfa Scientific Designs, Inc. American Screening Corporation, Inc. BD Medical device company Beckman Coulter Inc. Biomerica, Inc. Bio-Rad Laboratories, Inc. Danaher Corporation F. Hoffmann-La Roche AG LifeSign LLC Medtronic plc Nano-Ditech Corporation Nexus Dx, Inc. Nova Biomedical Corporation PTS Diagnostics Sekisui Medical Co., Ltd. Siemens Healthineers AG Werfen Life Group For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets